1. Alcohol exacerbates psychosocial stress-induced neuropsychiatric symptoms: Attenuation by geraniol.
- Author
-
Ben-Azu B, Adebesin A, Moke GE, Ojiokor VO, Olusegun A, Jarikre TA, Akinluyi ET, Olukemi OA, Omeiza NA, Nkenchor P, Niemogha AR, Ewere ED, Igwoku C, and Omamogho F
- Subjects
- Animals, Male, Mice, Brain drug effects, Brain metabolism, Social Defeat, Acyclic Monoterpenes pharmacology, Acyclic Monoterpenes therapeutic use, Stress, Psychological psychology, Stress, Psychological metabolism, Stress, Psychological drug therapy, Stress, Psychological complications, Ethanol toxicity, Ethanol pharmacology, Terpenes pharmacology, Terpenes therapeutic use
- Abstract
Adaptation to psychosocial stress is psychologically distressing, initiating/promoting comorbidity with alcohol use disorders. Emerging evidence moreover showed that ethanol (EtOH) exacerbates social-defeat stress (SDS)-induced behavioral impairments, neurobiological sequelae, and poor therapeutic outcomes. Hence, this study investigated the effects of geraniol, an isoprenoid monoterpenoid alcohol with neuroprotective functions on EtOH escalated SDS-induced behavioral impairments, and neurobiological sequelae in mice. Male mice chronically exposed to SDS for 14 days were repeatedly fed with EtOH (2 g/kg, p. o.) from days 8-14. From days 1-14, SDS-EtOH co-exposed mice were concurrently treated with geraniol (25 and 50 mg/kg) or fluoxetine (10 mg/kg) orally. After SDS-EtOH translational interactions, arrays of behavioral tasks were examined, followed by investigations of oxido-inflammatory, neurochemicals levels, monoamine oxidase-B and acetylcholinesterase activities in the striatum, prefrontal-cortex, and hippocampus. The glial fibrillary acid protein (GFAP) expression was also quantified in the prefrontal-cortex immunohistochemically. Adrenal weights, serum glucose and corticosterone concentrations were measured. EtOH exacerbated SDS-induced low-stress resilience, social impairment characterized by anxiety, depression, and memory deficits were attenuated by geraniol (50 and 100 mg/kg) and fluoxetine. In line with this, geraniol increased the levels of dopamine, serotonin, and glutamic-acid decarboxylase enzyme, accompanied by reduced monoamine oxidase-B and acetylcholinesterase activities in the prefrontal-cortex, hippocampus, and striatum. Geraniol inhibited SDS-EtOH-induced adrenal hypertrophy, corticosterone, TNF-α, IL-6 release, malondialdehyde and nitrite levels, with increased antioxidant activities. Immunohistochemical analyses revealed that geraniol enhanced GFAP immunoreactivity in the prefrontal-cortex relative to SDS-EtOH group. We concluded that geraniol ameliorates SDS-EtOH interaction-induced behavioral changes via normalization of neuroimmune-endocrine and neurochemical dysregulations in mice brains., Competing Interests: Declaration of competing interest Authors declare that they have no conflict of interest and all experiments were approved and performed under the guidelines of Faculty of Basic Medical Sciences, Delta State University Animals Ethic Committee (REC/FBMS/DELSU/22/148) and the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication number: 85–23, revised 1985)., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF